Emyria is developing MDMA- and psilocybin-assisted therapies to treat PTSD and treatment-resistant depression, utilizing real-world data collection to refine these treatment models. The company aims to improve health outcomes for patients facing significant mental health challenges while advancing a proprietary pipeline of novel drug-assisted therapies for neurological conditions.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals with PTSD and treatment-resistant depression do not respond to existing therapies, highlighting the need for innovative treatment options. Traditional mental healthcare often lacks personalized approaches and comprehensive data collection to optimize treatment efficacy.
Solution
Emyria is developing MDMA- and psilocybin-assisted therapy programs for PTSD and treatment-resistant depression, enhanced by rigorous real-world data collection. Emyria's clinics serve as learning environments to refine and scale these treatment models. The company leverages patient data to advance a proprietary pipeline of MDMA-inspired medicines and new treatment approaches, targeting the next generation of drug-assisted therapies and select neurological conditions.
Target Audience
The primary target audience includes individuals suffering from PTSD and treatment-resistant depression, as well as healthcare providers seeking innovative treatment options for these conditions.
Features
- Active clinical services trialing MDMA and psilocybin for PTSD and depression
- Proprietary drug development pipeline working with novel MDMA-like compounds
- Focus on optimizing patient outcomes and experiences
- Stringent clinical governance framework that includes ethics-endorsed care models
- Comprehensive data governance and privacy policies